{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:01:35Z","timestamp":1791669695418,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11606-026-10408-4","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:13:26Z","timestamp":1776262406000},"page":"2890-2900","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017\u20132023: Demographic, Income, and Insurance Associations"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-8507","authenticated-orcid":false,"given":"Molly","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"10","key":"10408_CR1","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177-e232. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.010.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"10408_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/17460441.2013.741580","volume":"8","author":"DG Parkes","year":"2013","unstructured":"Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2013;8(2):219-244. https:\/\/doi.org\/10.1517\/17460441.2013.741580.","journal-title":"Expert Opin Drug Discov."},{"issue":"10193","key":"10408_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"The Lancet."},{"issue":"4","key":"10408_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2337\/dc19-1943","volume":"43","author":"CV Dave","year":"2020","unstructured":"Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013\u20132018. Diabetes Care. 2020;43(4):921-924. https:\/\/doi.org\/10.2337\/dc19-1943.","journal-title":"Diabetes Care."},{"issue":"6","key":"10408_CR5","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.xkme.2025.101013","volume":"7","author":"P Hansrivijit","year":"2025","unstructured":"Hansrivijit P, Ortega-Montiel J, Wexler DJ, Patorno E, Paik JM. Utilization Trends of Dual GIP\/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes. Kidney Med. 2025;7(6):101013. https:\/\/doi.org\/10.1016\/j.xkme.2025.101013.","journal-title":"Kidney Med."},{"issue":"24","key":"10408_CR6","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2025.4735","volume":"333","author":"C Kim","year":"2025","unstructured":"Kim C, Ross JS, Jastreboff AM, et al. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US. JAMA. 2025;333(24):2203. https:\/\/doi.org\/10.1001\/jama.2025.4735.","journal-title":"JAMA."},{"key":"10408_CR7","doi-asserted-by":"publisher","unstructured":"Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm. 2024;30(8):860\u2013867. https:\/\/doi.org\/10.18553\/jmcp.2024.23332.","DOI":"10.18553\/jmcp.2024.23332"},{"issue":"12","key":"10408_CR8","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182.","journal-title":"JAMA Health Forum."},{"issue":"6","key":"10408_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7326\/ANNALS-24-02878","volume":"178","author":"C Shadbolt","year":"2025","unstructured":"Shadbolt C, Elkin J, Schilling C, Hua X, Choong PFM, Dowsey MM. National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022. Ann Intern Med. 2025;178(6):896-898. https:\/\/doi.org\/10.7326\/ANNALS-24-02878.","journal-title":"Ann Intern Med."},{"key":"10408_CR10","doi-asserted-by":"publisher","unstructured":"Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm. 2024;30(8):860\u2013867. https:\/\/doi.org\/10.18553\/jmcp.2024.23332.","DOI":"10.18553\/jmcp.2024.23332"},{"issue":"11","key":"10408_CR11","doi-asserted-by":"publisher","first-page":"e5427","DOI":"10.1097\/GOX.0000000000005427","volume":"11","author":"R Fezza","year":"2023","unstructured":"Fezza R, Rains B, Fezza T, Fezza JP. Emerging Anesthesia Risks with Semaglutide. Plast Reconstr Surg Glob Open. 2023;11(11):e5427. https:\/\/doi.org\/10.1097\/GOX.0000000000005427.","journal-title":"Plast Reconstr Surg Glob Open."},{"issue":"10","key":"10408_CR12","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00125-023-05962-z","volume":"66","author":"T Karagiannis","year":"2023","unstructured":"Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023;66(10):1859-1868. https:\/\/doi.org\/10.1007\/s00125-023-05962-z.","journal-title":"Diabetologia."},{"key":"10408_CR13","doi-asserted-by":"publisher","unstructured":"Pandey A, Ye Y, Wells CR, Singer BH, Galvani AP. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings of the National Academy of Sciences. 2024;121(43). https:\/\/doi.org\/10.1073\/pnas.2412872121.","DOI":"10.1073\/pnas.2412872121"},{"key":"10408_CR14","doi-asserted-by":"publisher","unstructured":"Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. J Comp Eff Res. 2025;14(9). https:\/\/doi.org\/10.57264\/cer-2025-0083.","DOI":"10.57264\/cer-2025-0083"},{"key":"10408_CR15","unstructured":"Agency for Healthcare Research and Quality. MEPS-HC Panel Design and Collection Process. Household Component. December 2, 2022."},{"key":"10408_CR16","unstructured":"Agency for Healthcare Research and Quality. MEPS HC-036: 1996\u20132022 Pooled Linkage File for Common Variance Structure. Technical and Programming Information. August 2024."},{"key":"10408_CR17","doi-asserted-by":"crossref","unstructured":"Pearson S, Whaley C, Emond S. Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions. Institute for Clinical and Economic Review. April 9, 2025.","DOI":"10.57264\/cer-2025-0083"},{"issue":"1","key":"10408_CR18","doi-asserted-by":"publisher","first-page":"e011649","DOI":"10.1161\/CIRCOUTCOMES.124.011649","volume":"18","author":"RL Tisdale","year":"2025","unstructured":"Tisdale RL, Beyene TJ, Tang W, Heidenreich P, Asch SM, Yong CM. Racial and Ethnic Differences in Semaglutide Prescriptions for Veterans With Overweight or Obesity in the Veterans Affairs Healthcare System. Circ Cardiovasc Qual Outcomes. 2025;18(1):e011649. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.124.011649.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"19","key":"10408_CR19","doi-asserted-by":"publisher","first-page":"e025545","DOI":"10.1161\/JAHA.121.025545","volume":"11","author":"Y Lu","year":"2022","unstructured":"Lu Y, Liu Y, Krumholz HM. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United\u00a0States. J Am Heart Assoc. 2022;11(19):e025545. https:\/\/doi.org\/10.1161\/JAHA.121.025545.","journal-title":"J Am Heart Assoc."},{"key":"10408_CR20","doi-asserted-by":"publisher","first-page":"101398","DOI":"10.1016\/j.lanepe.2025.101398","volume":"56","author":"RB Hasselbalch","year":"2025","unstructured":"Hasselbalch RB, Andrea MK, Nols\u00f8e CV, et al. Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark. The Lancet Regional Health - Europe. 2025;56:101398. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101398.","journal-title":"The Lancet Regional Health - Europe."},{"issue":"6","key":"10408_CR21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7326\/ANNALS-24-02878","volume":"178","author":"C Shadbolt","year":"2025","unstructured":"Shadbolt C, Elkin J, Schilling C, Hua X, Choong PFM, Dowsey MM. National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022. Ann Intern Med. 2025;178(6):896-898. https:\/\/doi.org\/10.7326\/ANNALS-24-02878","journal-title":"Ann Intern Med."},{"issue":"7","key":"10408_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.2023.13872","volume":"330","author":"R Alhiary","year":"2023","unstructured":"Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA. 2023;330(7):650. https:\/\/doi.org\/10.1001\/jama.2023.13872.","journal-title":"JAMA."},{"issue":"9","key":"10408_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/jama.2024.0919","volume":"331","author":"R Alhiary","year":"2024","unstructured":"Alhiary R, Gabriele S, Kesselheim AS, Tu SS, Feldman WB. Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. 2024;331(9):794. https:\/\/doi.org\/10.1001\/jama.2024.0919.","journal-title":"JAMA."},{"key":"10408_CR24","doi-asserted-by":"publisher","unstructured":"Saikia H, Baruah PR, Saikia AL. Cost Analysis of DPP4 and SGLT2 Inhibitors - \u201cDilemma of the Prescribing Physician - Which Brand to Choose?\u201d Journal of Pharmaceutical Research. 2024;23(2):77\u201382. https:\/\/doi.org\/10.18579\/jopcr\/v23.2.15.","DOI":"10.18579\/jopcr\/v23.2.15"},{"key":"10408_CR25","doi-asserted-by":"publisher","unstructured":"Wisniewski B, Smith E, Kaur J, Sherling C, Vanapalli S, Lussier M. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019\u20132023. J Manag Care Spec Pharm. 2024;30(1):34\u201342. https:\/\/doi.org\/10.18553\/jmcp.2024.30.1.34.","DOI":"10.18553\/jmcp.2024.30.1.34"},{"issue":"1","key":"10408_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12875-025-02709-0","volume":"26","author":"S Yun","year":"2025","unstructured":"Yun S, Hurren K, Holleman R, Klamerus M, Tremblay A, Sussman JB. Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention. BMC Primary Care. 2025;26(1):78. https:\/\/doi.org\/10.1186\/s12875-025-02709-0.","journal-title":"BMC Primary Care."},{"issue":"6","key":"10408_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.7326\/ANNALS-24-01449","volume":"178","author":"AN Makam","year":"2025","unstructured":"Makam AN, Bailey L, Anderson N, Bellitti K, Skinner S, Nguyen OK. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program. Ann Intern Med. 2025;178(6):808-818. https:\/\/doi.org\/10.7326\/ANNALS-24-01449.","journal-title":"Ann Intern Med."},{"key":"10408_CR28","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.lana.2024.100759","volume":"34","author":"LA Rodriguez","year":"2024","unstructured":"Rodriguez LA, Finertie H, Neugebauer RS, et al. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. The Lancet Regional Health - Americas. 2024;34:100759. https:\/\/doi.org\/10.1016\/j.lana.2024.100759.","journal-title":"The Lancet Regional Health - Americas."},{"issue":"6","key":"10408_CR29","doi-asserted-by":"publisher","first-page":"e2317886","DOI":"10.1001\/jamanetworkopen.2023.17886","volume":"6","author":"J Luo","year":"2023","unstructured":"Luo J, Feldman R, Callaway Kim K, et al. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease. JAMA Netw Open. 2023;6(6):e2317886. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17886.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"10408_CR30","doi-asserted-by":"publisher","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807. https:\/\/doi.org\/10.1136\/bmjopen-2022-061807.","journal-title":"BMJ Open."},{"key":"10408_CR31","unstructured":"U.S. Food & Drug Administration. FDA\u2019s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. August 8, 2025."},{"issue":"12","key":"10408_CR32","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182.","journal-title":"JAMA Health Forum."},{"key":"10408_CR33","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.ajmo.2025.100100","volume":"13","author":"KJ Spinelli","year":"2025","unstructured":"Spinelli KJ, Oakes AH, Chiu ST, et al. Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists. Am J Med Open. 2025;13:100100. https:\/\/doi.org\/10.1016\/j.ajmo.2025.100100.","journal-title":"Am J Med Open."},{"key":"10408_CR34","doi-asserted-by":"publisher","unstructured":"Scagliusi FB, Gualano B, Andreassen P, SturtzSreetharan C, Jensen SD, Brewis A. The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective. Obesity. Published online November 12, 2025. https:\/\/doi.org\/10.1002\/oby.70069.","DOI":"10.1002\/oby.70069"},{"key":"10408_CR35","doi-asserted-by":"publisher","unstructured":"Ugwu H, Willis E, Pickett M. Electronic word-of-mouth and off-label use of Ozempic and other GLP-1 medications. J Health Psychol. Published online January 28, 2026. https:\/\/doi.org\/10.1177\/13591053251409613.","DOI":"10.1177\/13591053251409613"},{"issue":"1","key":"10408_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/asj\/sjad211","volume":"44","author":"SH Han","year":"2023","unstructured":"Han SH, Safeek R, Ockerman K, et al. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthet Surg J. 2023;44(1):60-67. https:\/\/doi.org\/10.1093\/asj\/sjad211.","journal-title":"Aesthet Surg J."},{"issue":"6","key":"10408_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/diabetology6060052","volume":"6","author":"V Altabas","year":"2025","unstructured":"Altabas V, Orlovi\u0107 Z, Bareti\u0107 M. Addressing the Shortage of GLP-1 RA and Dual GIP\/GLP-1 RA-Based Therapies\u2014A Systematic Review. Diabetology. 2025;6(6):52. https:\/\/doi.org\/10.3390\/diabetology6060052.","journal-title":"Diabetology."},{"key":"10408_CR38","unstructured":"Tovino SA. The Case for Ozempic. Available at SSRN 6299640. Published online 2026."},{"issue":"12","key":"10408_CR39","doi-asserted-by":"publisher","first-page":"e0005516","DOI":"10.1371\/journal.pgph.0005516","volume":"5","author":"SD Jensen","year":"2025","unstructured":"Jensen SD, Gualano B, Andreassen P, Scagliusi FB, SturtzSreetharan C, Brewis A. Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss. PLOS Global Public Health. 2025;5(12):e0005516. https:\/\/doi.org\/10.1371\/journal.pgph.0005516.","journal-title":"PLOS Global Public Health."},{"issue":"1","key":"10408_CR40","doi-asserted-by":"publisher","first-page":"e2455222","DOI":"10.1001\/jamanetworkopen.2024.55222","volume":"8","author":"MI Podolsky","year":"2025","unstructured":"Podolsky MI, Raquib R, Shafer PR, Hempstead K, Ellis RP, Stokes AC. Factors Associated With Semaglutide Initiation Among Adults With Obesity. JAMA Netw Open. 2025;8(1):e2455222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.55222.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"10408_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2337\/cd23-0023","volume":"41","author":"HP Whitley","year":"2023","unstructured":"Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1\/GIP Receptor Agonist Shortages. Clin Diab. 2023;41(3):467-473. https:\/\/doi.org\/10.2337\/cd23-0023.","journal-title":"Clin Diab."},{"key":"10408_CR42","doi-asserted-by":"publisher","unstructured":"Botana L\u00f3pez M, Camafort Babkowski M, Campuzano Ruiz R, et al. Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain. Adv Ther. 2024;41(9):3569\u20133584.:https:\/\/doi.org\/10.1007\/s12325-024-02938-2.","DOI":"10.1007\/s12325-024-02938-2"},{"issue":"4","key":"10408_CR43","doi-asserted-by":"publisher","first-page":"e250905","DOI":"10.1001\/jamahealthforum.2025.0905","volume":"6","author":"JH Hwang","year":"2025","unstructured":"Hwang JH, Laiteerapong N, Huang ES, Mozaffarian D, Fendrick AM, Kim DD. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity. JAMA Health Forum. 2025;6(4):e250905. https:\/\/doi.org\/10.1001\/jamahealthforum.2025.0905.","journal-title":"JAMA Health Forum."},{"issue":"6","key":"10408_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.7326\/ANNALS-24-01449","volume":"178","author":"AN Makam","year":"2025","unstructured":"Makam AN, Bailey L, Anderson N, Bellitti K, Skinner S, Nguyen OK. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program. Ann Intern Med. 2025;178(6):808-818. https:\/\/doi.org\/10.7326\/ANNALS-24-01449.","journal-title":"Ann Intern Med."},{"key":"10408_CR45","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.ajmo.2025.100100","volume":"13","author":"KJ Spinelli","year":"2025","unstructured":"Spinelli KJ, Oakes AH, Chiu ST, et al. Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists. Am J Med Open. 2025;13:100100. https:\/\/doi.org\/10.1016\/j.ajmo.2025.100100.","journal-title":"Am J Med Open."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10408-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:02:46Z","timestamp":1785513766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10408-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10408"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10408-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they do not have a conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}